Clinical trials: Hypotension and Shock
Hypotension and Shock
BP Management System User Acceptance Testing
This is a feasibility study for an investigational clinical decision support system ("the System") intended to optimize the management of blood pressure (BP) for patients during vasopressor infusion.
- Trial name
- NCT04688450
- Testing
- VIGORIS Blood Pressure Management Clinical Decision Support System
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Andrew Tomas Reisner
Hypotension and Shock, Excessive Amount of Blood / Fluid Infusion
Predict Fluid Responsiveness in Spinal Anesthesia
Spinal anesthesia is still the regional anesthesia technique most widely employed in everyday clinical practice. The most feared and common of its well known side effects consist in an abrupt reduction of systemic vascular…
- Trial name
- CERU-1401 (NCT02070276)
- Testing
- Trans-thoracic echocardiography, Passive Leg Raising Test
- Where
- Switzerland
- Volunteers
- 429 people
- Sponsor
- Ente Ospedaliero Cantonale, Bellinzona
Septic Shock
Midodrine Use in Septic Shock
The investigators aim to perform a randomized, double-blind, placebo-controlled trial to investigate the efficacy of midodrine in decreasing time to IV vasopressor liberation in patients with septic shock.
- Trial name
- NCT03706053
- Testing
- Midodrine Hydrochloride
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Septic Shock
Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock
The purpose of this trial is to investigate the potential of FE 202158 as a treatment which can stabilize blood pressure for treatment of patients in early septic shock.
- Trial name
- NCT01612676
- Testing
- FE 202158
- Where
- 4 sites in Belgium, Denmark
- Volunteers
- 31 people
- Sponsor
- Ferring Pharmaceuticals
Septic Shock
Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study
The investigators propose a dose finding study to determine the feasibility of Angiotensin II (AII) to increase mean arterial pressure in high-output shock.
- Trial name
- ATHOS (NCT01393782)
- Testing
- Angiotensin II
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- George Washington University
Septic Shock, Fluid Therapy
Fluid Balance in the ICU - Interventions to Minimize Fluids in Patients With Septic Shock
The purpose of the study is to determine if a protocol that assesses patients' daily fluid intake and output can decrease the overall amount of fluid patients receive during the first five days in the ICU.
- Conditions
- Septic Shock, Fluid Therapy, Hypotension
- Trial name
- NCT02473718
- Testing
- Fluid minimization protocol, Ultrasound
- Volunteers
- 82 people
- Sponsor
- Washington University School of Medicine
Hypotension, Shock
Optimal VAsopressor titraTION Pilot Randomized Controlled Trial
The purpose of this research study is to determine if it is better to give vasopressors to patients to maintain a higher blood pressure target versus a lower blood pressure target.
- Trial name
- OVATION (NCT01800877)
- Testing
- Vasopressors
- Where
- 10 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Francois Lamontagne
Shock, Surgical, Shock
Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients
The current standard of catecholamine vasopressor management of perioperative hypotension in kidney transplant patients carries significant risks and falls short in many ways.
- Conditions
- Shock, Surgical, Shock, Hypotension and Shock, Kidney Transplant; Complications
- Trial name
- NCT04529005
- Testing
- Angiotensin II
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Illinois Chicago
Septic Shock
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
The purpose of this trial was to examine the safety and tolerability, pharmacokinetics of FE 202158 and to assess whether it can stabilize blood pressure and reduce vascular (blood vessel) leakage.
- Trial name
- NCT01000649
- Testing
- FE 202158 1.25, FE 202158 2.5, FE 202158 3.75
- Where
- 16 sites in United States, Belgium and 2 more
- Volunteers
- 53 people
- Sponsor
- Ferring Pharmaceuticals
Septic Shock
Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis
Multicenter, prospective, phase 3 randomized non-blinded interventional trial of fluid treatment strategies in the first 24 hours for patients with sepsis-induced hypotension.
- Trial name
- CLOVERS (NCT03434028)
- Testing
- Early Vasopressors, Early Fluids
- Where
- 50 sites in United States
- Volunteers
- 1,563 people
- Sponsor
- Massachusetts General Hospital
Sepsis, Septic Shock
Ascorbic Acid (Vitamin C) Infusion in Human Sepsis
The major goal of this project is to determine whether intravenously infused ascorbic acid is safe for use as a viable therapeutic strategy in adult humans with sepsis.
- Conditions
- Sepsis, Septic Shock, Hypotension, Acute Lung Injury
- Trial name
- NCT01434121
- Testing
- Ascorbic Acid
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Virginia Commonwealth University
Septic Shock, Hypotension
Esmolol to Treat the Hemodynamic Effects of Septic Shock
The main purpose of this study is to determine the effects of controlling the heart rate of patients with septic shock using an intravenous medication called esmolol.
- Conditions
- Septic Shock, Hypotension, Tachycardia
- Trial name
- NCT02369900
- Testing
- Esmolol, Saline
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Beth Israel Deaconess Medical Center
Hypotension, Shock
Transcutaneous pO2, Transcutaneous pCO2 and Central Venous SO2 Variations to Define Fluid Responsiveness
Fluid challenge is often carried out in critical ill patients. Its responsiveness usually requires invasive monitoring. To use non-invasive methods is very tempting.
- Conditions
- Hypotension, Shock, Fluid Challenge, Fluid Responsiveness
- Trial name
- NCT01941472
- Testing
- fluid challenge
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Catecholamine-resistant Hypotension (CRH), Distributive Shock
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
This is a Phase 3, double-blind, randomized study of LJPC-501 (angiotensin II) in adult patients diagnosed with catecholamine-resistant hypotension (CRH) conducted in multiple centers globally.
- Conditions
- Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
- Trial name
- ATHOS-3 (NCT02338843)
- Testing
- LJPC-501
- Where
- 115 sites in United States, Australia and 8 more
- Volunteers
- 344 people
- Sponsor
- La Jolla Pharmaceutical Company